Taiwan Associated Genetic and Nongenetic Small Vessel Disease

ConditionsCerebral Small Vessel Diseases Cadasil HTRA1-Related Autosomal Dominant Cerebral Angiopathy COL4A1-Related Brain Small Vessel Disease With Haemorrhage Fabry Disease Magnetic Resonance Imaging Next-generation Sequencing Stroke

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorNational Taiwan University Hospital

About this trial

The TAG-SVD enrolled patients with clinical and neuroimaging features of cerebral small vessel disease (CSVD). All enrolled patients will receive next-generation sequence (NGS) with probes designed to target five candidate CSVD genes, and patients will be divided into genetic or non-genetic groups accordingly. Their clinical features and outcome will be followed for at least 2 years.

Eligibility criteria

Qualifiers

stroke (especially small vessel occlusion type of ischaemic stroke, spontaneous ICH or young stroke)

cognitive impairment or dementia

gait disturbance

parkinsonism (especially vascular parkinsonism features)

Disqualifiers

MRI evidence of CSVD due to other inflammatory, malignancy, or structural lesions

patients or family members not willing to sign informed consent

Trial design

Treatments tested in this trial

Treatment groups

500 Participants

are divided into 2 treatment groups

Locations

Department of Neurology, National Taiwan University Hospital100, Taipei Taiwan

Sponsors and collaborators

National Taiwan University Hospital

Lead sponsor

Source ClinicalTrials.gov